Current Search:  Neovascularization inhibitors (x)

View All Items

  • CSV Spreadsheet
(1 - 3 of 3)
Interleukin 10 (IL-10) selectively inhibits neovascularization in the Murine model of Retinopathy of Prematurity
Title
Interleukin 10 (IL-10) selectively inhibits neovascularization in the Murine model of Retinopathy of Prematurity.
Creator
Solomon, Evertz Stenson, Blanks, Janet C., Florida Atlantic University
Abstract/Description
Ocular neovascularization (NV), the development of new blood vessels in the eye, occurs when excessive vascular endothelial growth factor (VEGF) is produced. Eventually NV may lead to photoreceptor loss and or blindness, as it does in age-related macular degeneration (AMD), retinopathy of prematurity (ROP), and diabetic retinopathy. We tested the hypothesis that the anti-inflammatory cytokine, interleukin-10 (IL-10); can reduce inflammation and block NV in the affected areas of the retina....
Show moreOcular neovascularization (NV), the development of new blood vessels in the eye, occurs when excessive vascular endothelial growth factor (VEGF) is produced. Eventually NV may lead to photoreceptor loss and or blindness, as it does in age-related macular degeneration (AMD), retinopathy of prematurity (ROP), and diabetic retinopathy. We tested the hypothesis that the anti-inflammatory cytokine, interleukin-10 (IL-10); can reduce inflammation and block NV in the affected areas of the retina. The mouse ROP model was used for this study of NV. Seven day old neonates stayed in 75% oxygen for five days, then were given intraocular injection of IL-100 and NV was evaluated after seven days in room air. Controls were uninjected contralateral eyes. IL-l 0 strongly inhibited NV without affecting intra-retinal vessels. The selective inhibition of IL-10 on NV suggest a possible therapeutic use in infants with ROP, in diabetic retinopathy, and possibly, in AMD where inflammation is a risk factor.
Show less
Date Issued
2007
PURL
http://purl.flvc.org/fau/fd/FA00000833
Subject Headings
Neovascularization, Neovascularization inhibitors, Interleukin-10
Format
Document (PDF)
Hypoxia-regulated gene therapy for the treatment of subretinal neovascularization in age-related macular degeneration
Title
Hypoxia-regulated gene therapy for the treatment of subretinal neovascularization in age-related macular degeneration.
Creator
Smith, George Wesley Tyler., Charles E. Schmidt College of Science, Center for Complex Systems and Brain Sciences
Abstract/Description
Age-related macular degeneration (AMD) is the leading cause of blindness in the western world for people over 60 years of age. The most severe pathological event of AMD is choroidal neovascularization (CNV), the process of new vessel formation emerging from the choroid. The new vessels extend into the normally avascular photoreceptor cell layer, where they leak fluid and cause photoreceptor cell death. CNV is thought to be initiated by hypoxia and chronic inflammation, which occur due to...
Show moreAge-related macular degeneration (AMD) is the leading cause of blindness in the western world for people over 60 years of age. The most severe pathological event of AMD is choroidal neovascularization (CNV), the process of new vessel formation emerging from the choroid. The new vessels extend into the normally avascular photoreceptor cell layer, where they leak fluid and cause photoreceptor cell death. CNV is thought to be initiated by hypoxia and chronic inflammation, which occur due to abnormal, age-related changes within the retinal pigmented epithelium (RPE). These events cause increased expression of the angiogenic protein vascular endothelial growth factor (VEGF) via hypoxiainducible factor-1 (HIF-1), a transcription factor that is vital in regulation of cellular responses to hypoxic and inflammatory conditions. Increased VEGF signaling stimulates proliferation and migration of vascular endothelial cells and facilitates the neovascular process. To target the early pathological events that lead to CNV, we have engineered a novel gene therapy vector that uses HIF-1 regulation to stimulate production of an angiostatic protein, endostatin from the RPE. The purpose of this study was to characterize the activity of our hypoxiaregulated, RPE-specific promoter in vitro, and investigate the effects of regulated endostatin expression, driven by our regulated promoter, on CNV in a mousemodel. We found the regulated promoter construct has robust activity in vitro only in RPE cells, and is conditionally responsive in hypoxic conditions., In the laserinduced CNV model, CNV area was 80% smaller (P<0.0001) in eyes treated with the hypoxia-regulated, RPE-specific endostatin vector than in untreated eyes. CNV area was equally reduced in eyes treated with an unregulated endostatin vector (CMV-endostatin). However, less endostatin protein was detected in eyes treated with the regulated vector. Since it is unknown whether broad and constitutive endostatin expression will have damaging effects within the retina, it may be safer to limit its expression to pathological conditions. We have demonstrated that local, hypoxia-regulated expression of endostatin can effectively inhibit CNV, and thus, offers the further possibility of a prophylactic treatment for neovascular AMD.
Show less
Date Issued
2010
PURL
http://purl.flvc.org/FAU/2979379
Subject Headings
Retinal degeneration, Treatment, Eye, Aging, Neovascularization inhibitors
Format
Document (PDF)
Hypoxia-regulated glial cell-specific gene therapy to treat retinal neovascularization
Title
Hypoxia-regulated glial cell-specific gene therapy to treat retinal neovascularization.
Creator
Biswal, Manas Ranjan., Charles E. Schmidt College of Science, Center for Complex Systems and Brain Sciences
Abstract/Description
Diabetic retinopathy is an ischemic retinal neovascular disease causing vision loss among adults. The studies presented involve the design and testing of a gene therapy vector to inhibit retinal revascularization, similar to that found in diabetic retinopathy. Gene therapy has proven to be an effective method to introduce therapeutic proteins to treat retinal diseases. Targeting a specific cell type and expression of therapeutic proteins according to the tissue microenvironment should have an...
Show moreDiabetic retinopathy is an ischemic retinal neovascular disease causing vision loss among adults. The studies presented involve the design and testing of a gene therapy vector to inhibit retinal revascularization, similar to that found in diabetic retinopathy. Gene therapy has proven to be an effective method to introduce therapeutic proteins to treat retinal diseases. Targeting a specific cell type and expression of therapeutic proteins according to the tissue microenvironment should have an advantage over traditional gene therapy by avoiding unwanted transgene expression. Hypoxia plays a significant role in the pathophysiology of many retinal ischemic diseases. Retinal Mèuller cells provide structural and functional support to retinal neurons, as well as playing a significant role in retinal neovascularization. Targeting Mèuller cells may be an effective strategy to prevent retinal neovascularization under pathological conditions. ... The hypoxia regulated, glial specific vector successfully reduced the abnormal neovascularization in the periphery by 93% and reduced the central vasobliterated area by 90%. A substantial amount of exogenous endostatin was produced in the retinas of P17 OIR mice. A significant increase in human endostatin protein and reduced vascular endothelial growth factor (VEGF) were identified by Western blot and ELISA, respectively. These findings suggest hypoxia-regulated, glial cell-specific scAAV mediated gene expression may be useful to prevent blindness found in devastating retinal diseases involving neovascularization.
Show less
Date Issued
2012
PURL
http://purl.flvc.org/FAU/3359290
Subject Headings
Diabetic retinopathy, Research, Methodology, Gene therapy, Retinal degeneration, Treatment, Neovascularization inhibitors, Mitochondrial pathology, Retina, Cytology, Gene mapping
Format
Document (PDF)